Drug Profile
Bempedoic acid - Esperion Therapeutics
Alternative Names: ESP-55016; ETC-1002; NEXLETOL; NILEMDO; NilemdoLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Esperion Therapeutics
- Developer Daiichi Sankyo Europe; Esperion Therapeutics; Otsuka Pharmaceutical
- Class Antihyperlipidaemics; Antihypertensives; Dicarboxylic acids; Fatty acids; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; ATP citrate (pro S) lyase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Dyslipidaemias; Hypercholesterolaemia
- Preregistration Cardiovascular disorders
- Phase I Hypertension
Most Recent Events
- 22 Mar 2024 Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends approval of Bempedoic acid for Cardiovascular disorders (Treatment-experienced) in European union
- 21 Mar 2024 Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion for bempedoic acid in Cardiovascular disorders
- 07 Mar 2024 FDA assigns PDUFA action date of 31/03/2024 for Bempedoic acid for Cardiovascular disorders